Partial sarcasm. After I made the case for pri
Post# of 148155
After I made the case for pricing leronlimab at 35k a year*, Nader announced the new pricing for the drug would be 35k a year. After I laid out a conservative case for a $300 share price, Nader said at the end of an investors call that the share price could end up being worth high three figures. After I posited leronlimab's use in extreme cases of influenza they announced it's possible use with coronavirus.
*One of the things I mentioned was at that price point it might be used as a prophylaxis for cancer.